US approves Gilead's twice-yearly injection to prevent HIV
AP This photo provided by Gilead Sciences shows packaging for the company's HIV prevention medication, Yeztugo, (lenacapvir) at a manufacturing facility in La Verne, Calif., in June 2025.
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.
Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have yet to make a significant dent in global infections.
"This is a historic day in the decades-long fight against HIV," Gilead chairman and chief executive Daniel O'Day said in a statement.
Lenacapavir, marketed under the brand name Yeztugo, has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine. The company conducted two large clinical trials. The first, involving more than 2,000 women in sub-Saharan Africa, resulted in a 100 percent reduction in infections and demonstrated superiority over the daily oral pill Truvada.
In the second trial, involving over 2,000 men and gender-diverse individuals, only two infections were recorded - a 99.9 percent prevention rate, again surpassing Truvada.Reported side effects included injection site reactions, headache, and nausea.Results from both trials were published in The New England Journal of Medicine, and the journal Science named lenacapavir its 2024 "Breakthrough of the Year."- Price concerns dampen hope -Despite the impressive results, optimism may be tempered by the drug's cost -- a list price of $28,218 per year in the United States, Gilead spokeswoman Blair Baumwell told AFP in an email Wednesday.
An earlier long-acting HIV prevention shot -- cabotegravir, which is injected every two months and was approved by the FDA in 2021 -- costs tens of thousands of dollars per year and has yet to make a major global impact. Lenacapavir's current list price for its previously approved use as a treatment for HIV is $39,000 annually.Baumwell said the $28,000-plus per year cost for Lenacapavir as a preventive drug is "in line with" those of existing PrEP products and that the company inspects insurers to cover it."We are working to make Yeztugo accessible for anyone who needs or wants it and expect to see broad insurance coverage," she said in the email.Activists are urging Gilead to drastically cut the price to help end the HIV pandemic."Even high-income countries will not be able to afford widescale use of lenacapavir at prices above US $20,000 per year," said Andrew Hill of Liverpool University, who led a team of chemists and scientists that found it could be mass-produced and sold for as little as $25 per person per year."I congratulate Gilead and US partners for advancing this important innovation," added Winnie Byanyima, under-secretary-general of the United Nations. "Lenacapavir could be the tool we need to bring new infections under control -- but only if it is priced affordably and made available to everyone who could benefit."In October, Gilead signed agreements with six pharmaceutical companies to produce and distribute generic versions of the drug, pending regulatory approval, in 120 low- and middle-income countries.Because it will take time for those countries to begin production, the company also announced a separate deal in December with the Global Fund -- an international partnership established by the United Nations, alongside the US President's Emergency Plan for AIDS Relief (PEPFAR) and others -- to purchase doses for two million people.However, cuts to the PEPFAR program under President Donald Trump's administration have cast uncertainty over the future of that agreement.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
an hour ago
- Indian Express
US FDA approves HIV prevention drug: Why is this a breakthrough?
A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States' Food and Drug Administration. With better compliance expected — instead of daily pills on a shot every two months that people have to take at the moment — it is one of the most anticipated developments in the field of HIV prevention. The Lenacapavir injection — sold as Yeztugo by pharmaceutical giant Gilead — was approved based on the results of two Phase 3 trials that showed 99.9% of individuals remained HIV negative with the two shots taken annually. 'FDA approval … paves the way for WHO prequalification, which can accelerate national regulatory approvals … and procurement by donor agencies like the Global Fund… Lenacapavir's discreet, long-acting formulation may help overcome key barriers such as daily pill burden, frequent clinic visits and stigma associated with HIV prevention,' the World Health Organization (WHO) said. Lenacapavir is an anti-retroviral medication that can be used to treat as well as prevent HIV. As Sunlenca, it is used in combination with other antiretroviral drugs for the treatment of people who have been on pills for a very long time and are resistant to multiple drugs. As Yestugo, it is a pre-exposure prophylaxis (PrEP) to prevent the infection. The drug works by binding with the HIV capsid — a protein shell that protects the virus' genetic material. It then disrupts crucial steps needed for the virus to replicate and infect new cells. PrEP or pre-exposure prophylaxis is a drug or injectable meant to prevent HIV infection in people at a higher risk of contracting the disease. These medicines can reduce the risk of acquiring HIV infection through sexual activity by 99% and through injection drug use by 74%. At present, there are several types of PrEP available — pills such as Truvada or Descovy, Dapivirine vaginal ring and the injectable Cabotegravir that has to be taken every two months. It is important to be tested for HIV before taking PrEP. While these medicines are also used in the treatment of HIV, they are prescribed in combination with other antiretrovirals. Given alone to a patient with HIV, they might develop resistance to the drugs. PrEP is usually recommended for people living with an HIV positive partner, those who frequently change partners, those who have sex with people with unknown HIV status, those who work in the sex industry, and those who use injectable drugs. Medicines for post exposure prophylaxis are also available to be used as an emergency measure in cases such as inadvertent exposure in a hospital setting, after condom failure, or during sexual assault. While generic versions of the PrEP pills are approved in India — Cabotegravir injection is also available through a sub-licensing contract — they are not widely used. This is mainly owing to the cost of the medicines and the fact that they are not yet part of the country's national programme, which already provides life-long treatment to all who have been diagnosed with HIV. The new injectable will cost USD 28,218 annually, remaining out of reach for many. Even in the US, usage remains low. Only 36% of the 1.2 million people who would have benefited from the medicine were prescribed it. Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
Mint
2 hours ago
- Mint
UK lawmakers to vote on assisted 'End of Life' Bill for terminally ill adults today
In a transformative step towards social policy change years after breakthrough legislation was made through legalisation of abortion in 1967, UK is set to vote on assisted death of terminally ill adults today. British lawmakers will deliberate on one of the most consequential social policy decisions on June 20. The first time the issue of assisted dying was discussed by the Members of Parliament was in November, when 330 voted members voted in support to 275. The proposed legislation, being shepherded through Parliament by Labour lawmaker Kim Leadbeater, underwent significant changes after the Terminally Ill Adults (End of Life) Bill faced months of scrutiny. The Labour MP Kim Leadbeater expressed confidence that the lawmakers will back the bill and said, 'We have the most robust piece of legislation in the world in front of us… and I know that many colleagues have engaged very closely with the legislation and will make their decision based on those facts and that evidence, and that cannot be disputed," AP reported. UK's Parliamentary Bills website describes it as, 'A Bill to allow adults who are terminally ill, subject to safeguards and protections, to request and be provided with assistance to end their own life; and for connected purposes.' Proponents of the Assisted Dying bill contend that individuals with terminal diagnosis must be provided with a choice at the end of their lives. However, this bill has faced scrutiny on several occasions and the opponents argue that the disabled and elderly could be at risk if the bill is passed. They are vulnerable of being coerced, directly or indirectly, to end their lives to relieve the burden on family members or save money, AP reported. Meanwhile, some argue that measures should be taken to improve palliative care to ease suffering. If the bill receives lawmaker's approval, terminally ill adults aged over 18 in England and Wales can apply for an assisted death. The Terminally Ill Adults (End of Life) Bill would be applicable on those individuals who are deemed to have less than six months to live. Proponents of the bill say wealthy individuals can travel to Switzerland, which allows foreigners to legally end their lives, while others have to face possible prosecution for helping their loves ones die.
Hindustan Times
3 hours ago
- Hindustan Times
Nephrologists bust 7 common myths about kidney disease: Is it actually preventable to is dialysis inevitable
According to the US-based National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), chronic kidney disease means that the kidneys are damaged and can't filter blood as they should. In an interview with HT Lifestyle, Dr Saiprasad Sahoo, senior consultant – nephrology, Manipal Hospital Bhubaneswar, shared that when it comes to maintaining kidney health, there are several myths that prevent people from taking the right steps to protect their kidneys. Also read | Do you overuse paracetamol? Urologist says it can increase kidney cancer risk; know these 10 everyday habits to avoid Dr Sahoo said, 'Kidneys are the silent warriors of the body – they filter waste, regulate electrolyte balance and blood pressure (BP), and keep us healthy. However, kidneys are susceptible to damage from various factors like poor diet, lifestyle habits, and underlying health conditions. Apart from lifestyle factors, kidney disease is also aggravated by known risk factors like diabetes and high blood pressure.' He added that to maintain kidney health, make conscious dietary choices and healthy lifestyle habits: 'Track your health parameters, eat good food, stay hydrated, avoid smoking, and manage your stress to ensure that your kidneys remain functional for a long time.' According to Dr Maria Bethsaida Manual, consultant, nephrology, and transplant physician, Manipal Hospital Whitefield, there are several myths surrounding kidney disease that 'lead to confusion, and delayed diagnosis and treatment'. Dr Sahoo and Dr Manual shared a bunch of myths they wish you would stop believing: 1. 'One such myth is that only the elderly are at risk of kidney disease. In reality, kidney issues can affect people of all ages, especially those with diabetes, high BP, or a family history of kidney issues,' Dr Sahoo said. 2. Does drinking water prevent kidney disease? According to Dr Manual: 'Staying hydrated is important to kidney health, but in some kidney diseases, such as End-Stage Renal Disease or Chronic Kidney Disease Stage 5, overhydration can be harmful.' 3. Dr Manual said that people think no symptoms mean the kidneys are fine. 'Kidney disease progresses silently, which means there are no symptoms until significant damage has already occurred,' she said. 4. 'Another popular belief is that herbal products can cure kidney disease. However, many herbal remedies contain unregulated and toxic substances that may be harmful to the kidneys. Therefore, please visit your doctor before using them exclusively,' Dr Sahoo said. 5. He added, 'Many people think that painkillers are harmless. But not many realise that overuse of non-steroidal anti-inflammatory drugs (NSAIDs) can damage the kidneys in people with existing risk factors.' 6. Another myth is that dialysis is inevitable if you have kidney disease. However, according to Dr Manual, 'Not all patients progress to ESRD (End-Stage Renal Disease). Many patients can maintain stable kidney function for years with proper lifestyle and medical treatment.' 7. Many also think that kidney disease is not preventable. Reacting to which, Dr Manual said, 'While not all forms are preventable, healthy lifestyle changes like controlling BP, blood glucose, and staying active gradually reduce the risk of disease progression.' Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
